Dabigatran

• Description :

  Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM) . Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) [1][2].

• Product Name Alternative :

  BIBR 953; BIBR 953ZW

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Thrombin

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Dabigatran.html

• Purity :

  98.06

• Solubility :

  0.1 M HCl : 12.5 mg/mL (ultrasonic) |DMSO : < 1 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  N=C(N)C(C=C1)=CC=C1NCC2=NC3=CC(C(N(CCC(O)=O)C4=NC=CC=C4)=O)=CC=C3N2C

• Molecular Formula :

  C25H25N7O3

• Molecular Weight :

  471.51

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wienen W, Stassen JM, Priepke H, In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally activeprodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98 (1) :155-62.|[2]Hauel NH, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002 Apr 25;45 (9) :1757-66.|[3]Wienen W, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007 Aug;98 (2) :333-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [211914-51-1]